Cuban vaccine against lung cancer CIMAvax-EGF
August 6- The prestigious scientific journal Frontiers in Oncology published on August 3 the results of the research between the CIM and the Roswell Park Institute, in New York, in the United States, with the Cuban therapeutic vaccine against lung cancer CIMAvax-EGF.
The Center for Molecular Immunology (CIM) through its Twitter account announced that it is an ongoing study by the scientific institution based in New York, in the most advanced stage of patients in the second line of cervical cancer. non-small cell lung.
In this study, the vaccine is not used alone, but rather a combination of CIMAvax-EGF® with Nivolumab, an immunomodulatory drug. In this case we also showed that the combination was very safe and increased immunogenicity.
“At the same time we have a group of patients who are obtaining a very long survival. This gives us the possibility of identifying new biomarkers that allow us to anticipate populations that receive a benefit from the combination of both drugs”, she recently explained to
Cubadebate Dr. Tania Crombet, Director of Clinical Research at the CIM.
More than 10,000 Cuban patients have benefited from this vaccine in the different medical care scenarios (primary care, hospitals and institutes) of the national health system.
Real-world data on the use of CIMAvax-EGF® —as clinical research is called once product registration is completed— confirms the safety and effectiveness data that had been generated in previous Cuban research. Similarly, the data obtained by the Roswell Park Institute.
Frontiers in Oncology is the third most cited journal in its field with more than 155,000 citations and 60 million views across 17,000 articles. The publication of this research confirms the results obtained in the studies that are currently being conducted in Cuba with the drug and constitutes an important step in the visibility of Cuban science. (Source: Cubadebate)